{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:51Z","timestamp":1790801631459,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health CTSA","award":["UL1TR000128"],"award-info":[{"award-number":["UL1TR000128"]}]},{"name":"NIH-NIDCD","award":["R01 DC004555"],"award-info":[{"award-number":["R01 DC004555"]}]},{"name":"NIH-NIDCD","award":["R01 DC012588"],"award-info":[{"award-number":["R01 DC012588"]}]},{"name":"NIH-NIDCD","award":["R01 DC010202"],"award-info":[{"award-number":["R01 DC010202"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jcf.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T14:02:17Z","timestamp":1487944937000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis"],"prefix":"10.1016","volume":"16","author":[{"given":"Angela C.","family":"Garinis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Campbell P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Srikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Patrick","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Putterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Steyger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcf.2017.01.006_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijporl.2010.01.021","article-title":"Hearing loss in cystic fibrosis","volume":"74","author":"Martins","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9","key":"10.1016\/j.jcf.2017.01.006_bb0010","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/AAC.45.9.2502-2509.2001","article-title":"Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy","volume":"45","author":"Mulheran","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.006_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.otohns.2009.03.020","article-title":"Sensorineural hearing loss in patients with cystic fibrosis","volume":"141","author":"Cheng","year":"2009","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MCP.0b013e32833eebfd","article-title":"Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity","volume":"16","author":"Prayle","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2017.01.006_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/149.1.23","article-title":"Risk factors for the development of auditory toxicity in patients receiving aminoglycosides","volume":"149","author":"Moore","year":"1984","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.006_bb0030","first-page":"53","article-title":"Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions","volume":"10","author":"Md Daud","year":"2014","journal-title":"B-ENT"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.006_bb0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10162-014-0458-8","article-title":"Systemic lipopolysaccharide induces cochlear inflammation and exacerbates the synergistic ototoxicity of kanamycin and furosemide","volume":"15","author":"Hirose","year":"2014","journal-title":"J Assoc Res Otolaryngol"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/AAC.33.6.797","article-title":"Aminoglycoside-induced hearing loss in humans","volume":"33","author":"Brummett","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.006_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/149.1.23","article-title":"Risk factors for the development of auditory toxicity in patients receiving aminoglycosides","volume":"149","author":"Moore","year":"1984","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.006_bb0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s15010-009-8117-4","article-title":"Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.jcf.2017.01.006_bb0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0165-5876(03)00135-6","article-title":"The prevalence of neurosensorineural hearing loss among cystic fibrosis patients from Hospital de Clinicals de Porto Alegre","author":"Pilcher","year":"2003","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.006_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3766\/jaaa.14104","article-title":"Risk factors for hearing loss in patients with cystic fibrosis","volume":"27","author":"Tarshish","year":"2016","journal-title":"J Am Acad Audiol"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bjorl.2015.08.011","article-title":"High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients","volume":"81","author":"Geyer","year":"2015","journal-title":"Braz J Otorhinolaryngol"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0070","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/165.6.1026","article-title":"High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity","volume":"165","author":"Fausti","year":"1992","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.006_bb0075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0165-5876(02)00400-7","article-title":"The need for long-term audiologic follow-up of neonatal intensive care unit (NICU) graduates","volume":"67","author":"Yoon","year":"2003","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.006_bb0080","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/01.mlg.0000161355.28073.f5","article-title":"Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides","volume":"115","author":"Gurtler","year":"2005","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.006_bb0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14992027.2010.524253","article-title":"Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions","volume":"50","author":"Al-Malky","year":"2011","journal-title":"Int J Audiol"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.006_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2310\/7070.2007.0047","article-title":"Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin","volume":"36","author":"Mick","year":"2007","journal-title":"J Otolaryngol"},{"issue":"5","key":"10.1016\/j.jcf.2017.01.006_bb0095","first-page":"376","article-title":"Vancomycin ototoxicity and nephrotoxicity. A review","volume":"3","author":"Bailie","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.006_bb0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/00016480903015150","article-title":"No hearing loss after repeated courses of tobramycin in cystic fibrosis patients","volume":"130","author":"Scheenstra","year":"2010","journal-title":"Acta Otolaryngol"},{"issue":"7","key":"10.1016\/j.jcf.2017.01.006_bb0105","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.00995-05","article-title":"Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients","volume":"50","author":"Mulheran","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.006_bb0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ppul.20985","article-title":"A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis","volume":"44","author":"Van Meter","year":"2009","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl. A","key":"10.1016\/j.jcf.2017.01.006_bb0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0195-6701(91)90013-X","article-title":"Single daily dose therapy with aminoglycosides","volume":"18","author":"Nordstrom","year":"1991","journal-title":"J Hosp Infect"},{"issue":"5\u20136","key":"10.1016\/j.jcf.2017.01.006_bb0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/00016488809119511","article-title":"Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features","volume":"105","author":"Tran Ba Huy","year":"1988","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"10.1016\/j.jcf.2017.01.006_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/AAC.35.3.399","article-title":"Once-daily aminoglycoside therapy","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jcf.2017.01.006_bb0130","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2017.01.006_bb0135","series-title":"Cystic Fibrosis Foundation patient registry annual data report 2013 to the center directors","author":"Cystic Fibrosis Foundation","year":"2014"},{"key":"10.1016\/j.jcf.2017.01.006_bb0140","series-title":"Specification for instruments to measure aural acoustic impedance and admittance (aural acoustic immittance) S3.39-1987 R2007","author":"ANSI","year":"2007"},{"key":"10.1016\/j.jcf.2017.01.006_bb0145","series-title":"Specifications for audiometers (ANSI 3.6-1996)","author":"ANSI","year":"1996"},{"key":"10.1016\/j.jcf.2017.01.006_bb0150","series-title":"Specification for audiometers (ANSI S3.6-2010)","author":"ANSI","year":"2010"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.006_bb0155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1121\/1.393531","article-title":"Reference equivalent threshold levels for pure tone and 13 octare noise bands: insert earphone and TDH 49 earphone","volume":"79","author":"Cox","year":"1986","journal-title":"J Acoust Soc Am"},{"issue":"3","key":"10.1016\/j.jcf.2017.01.006_bb0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/01050399109074955","article-title":"Reference thresholds for EARTONE 3A insert earphones","volume":"20","author":"Poulsen","year":"1991","journal-title":"Scand Audiol"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00003446-199012000-00007","article-title":"High-frequency hearing thresholds in young adults using a commercially available audiometer","volume":"11","author":"Frank","year":"1990","journal-title":"Ear Hear"},{"key":"10.1016\/j.jcf.2017.01.006_bb0170","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1044\/jshd.2404.330","article-title":"Preferred method for clinical determination of pure-tone thresholds","volume":"24","author":"Carhart","year":"1959","journal-title":"J Speech Hear Disord"},{"key":"10.1016\/j.jcf.2017.01.006_bb0180","author":"Audiology AAO"},{"issue":"8","key":"10.1016\/j.jcf.2017.01.006_bb0185","first-page":"372","article-title":"Drug-induced ototoxicity.(clinical pharmacology) (clinical report)","volume":"27","author":"Sinxadi","year":"2009","journal-title":"CME Your SA J CPD"},{"issue":"3","key":"10.1016\/j.jcf.2017.01.006_bb0190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1345\/aph.1A216","article-title":"Ototoxicity induced by gentamicin and furosemide","volume":"36","author":"Bates","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.jcf.2017.01.006_bb0195","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.jcf.2017.01.006_bb0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF00181963","article-title":"Experimental, clinical and preventive aspects of ototoxicity","volume":"251","author":"Chiodo","year":"1994","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.jcf.2017.01.006_bb0205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.40.1.186","article-title":"Pharmacokinetics of vancomycin in adult cystic fibrosis patients","volume":"40","author":"Pleasants","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0210","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/AAC.23.6.897","article-title":"Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin","volume":"23","author":"Gatell","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2017.01.006_bb0215","series-title":"Aminoglycoside ototoxicity","first-page":"327","article-title":"Prospective studies of aminoglycoside ototoxicity in adults","author":"Matz","year":"1981"},{"issue":"Suppl. A","key":"10.1016\/j.jcf.2017.01.006_bb0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/4.suppl_A.73","article-title":"Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the Guinea pig","volume":"4","author":"Brummett","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcf.2017.01.006_bb0225","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/EDE.0b013e31812717fe","article-title":"Cigarette smoking and lung cancer: modeling effect modification of total exposure and intensity","volume":"18","author":"Lubin","year":"2007","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.jcf.2017.01.006_bb0230","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2006.10.077","article-title":"Relationship between cisplatin administration and the development of ototoxicity","volume":"24","author":"Rademaker-Lakhai","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcf.2017.01.006_bb0235","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/14992027.2014.893375","article-title":"Extended high-frequency (9\u201320kHz) audiometry reference thresholds in 645 healthy subjects","volume":"53","author":"Rodriguez-Valiente","year":"2014","journal-title":"nt J Audiol"},{"issue":"2","key":"10.1016\/j.jcf.2017.01.006_bb0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00003446-200104000-00009","article-title":"High-frequency (8 to 16kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone","volume":"22","author":"Frank","year":"2001","journal-title":"Ear Hear"},{"issue":"298","key":"10.1016\/j.jcf.2017.01.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5546","article-title":"Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity","volume":"7","author":"Koo","year":"2015","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.jcf.2017.01.006_bb0250","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ijporl.2015.09.004","article-title":"Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure","volume":"79","author":"Cross","year":"2015","journal-title":"Int J Pediatr Otorhinolaryngol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199317300139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199317300139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T03:08:19Z","timestamp":1556680099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199317300139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1569199317300139"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2017.01.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}